{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:04:52Z","timestamp":1780499092777,"version":"3.54.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Castleman\u2019s disease (CD) consists of a wide spectrum of rare disorders classified into unicentric CD and multicentric CD (MCD), based on the diffusion of disease distribution and the severity of clinical manifestations. While unicentric CD is characterized by a single lymph node involvement, MCD is defined by multiple lymph node station involvement with more prominent systemic symptoms. MCD is further subdivided into HHV-8 associated MCD, polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MCD, and idiopathic MCD (iMCD), which is also subdivided into iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly) and iMCD-NOS (not otherwise specified). The rarity of the disease makes it still poorly understood, as current insight is largely based on case reports and relatively small patient cohorts. Therefore, knowledge about the clinical details of the disease, histological correlations, complications, prognostic factors, and optimal treatment management remains incomplete. The potential offered by the creation of online data sharing makes the development of a registry specifically dedicated to CD a necessary step to conduct solid research on this condition. Building on the experience and widespread international reach of the AutoInflammatory Disease Alliance (AIDA) Network, the development of this registry can allow the recruitment of a sufficient number of patients to conduct robust research in all the fields of the disease. Moreover, the AIDA Network itself will enable multidisciplinary and integrated collaboration among the various figures necessary for the optimal diagnostic, clinical, and therapeutic management of patients affected by CD in its different forms.<\/jats:p>","DOI":"10.3389\/fmed.2025.1579182","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:38:50Z","timestamp":1756877930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and implementation of the International AIDA Network Castleman\u2019s disease registry"],"prefix":"10.3389","volume":"12","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sbalchiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Lazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Tharwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lampros","family":"Fotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Tufan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Hissaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wiesik-Szewczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gonz\u00e1lez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Karamanakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi Deniz","family":"Batu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haner","family":"Direskeneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamit","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahime","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa Ali","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghanema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Alibaz-\u00d6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Beecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Balistreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1182\/bloodadvances.2022007112","article-title":"Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease","volume":"6","author":"van Rhee","year":"2022","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"980679","DOI":"10.3389\/fmed.2022.980679","article-title":"The AutoInflammatory Diseases Alliance registry of monogenic autoinflammatory diseases","volume":"9","author":"Gaggiano","year":"2022","journal-title":"Front Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"930305","DOI":"10.3389\/fped.2022.930305","article-title":"Development and implementation of the AIDA international registry for patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome","volume":"10","author":"Della Casa","year":"2022","journal-title":"Front Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"931189","DOI":"10.3389\/fmed.2022.931189","article-title":"Development and implementation of the AIDA international registry for patients with Schnitzler\u2019s syndrome","volume":"9","author":"Sota","year":"2022","journal-title":"Front Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40123-022-00466-2","article-title":"Development and implementation of the AIDA international registry for patients with non-infectious scleritis","volume":"11","author":"Della Casa","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40123-022-00459-1","article-title":"Development and implementation of the AIDA international registry for patients with non-infectious uveitis","volume":"11","author":"Casa","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s11739-022-03038-1","article-title":"Development and implementation of the AIDA international registry for patients with Beh\u00e7et\u2019s disease","volume":"17","author":"Vitale","year":"2022","journal-title":"Intern Emerg Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"908501","DOI":"10.3389\/fmed.2022.908501","article-title":"Development and implementation of the AIDA international registry for patients with undifferentiated systemic AutoInflammatory diseases","volume":"9","author":"Della Casa","year":"2022","journal-title":"Front Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"878797","DOI":"10.3389\/fmed.2022.878797","article-title":"Development and implementation of the AIDA international registry for patients with still's disease","volume":"9","author":"Vitale","year":"2022","journal-title":"Front Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"926500","DOI":"10.3389\/fmed.2022.926500","article-title":"Development and implementation of the AIDA international registry for patients with VEXAS syndrome","volume":"9","author":"Vitale","year":"2022","journal-title":"Front Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5152\/TurkArchPediatr.2022.21303","article-title":"Rare autoinflammatory diseases","volume":"57","author":"Ba\u015faran","year":"2022","journal-title":"Turk Arch Pediatr"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3899\/jrheum.2024-0294","article-title":"Children with type I Interferonopathy: commonalities and diversities in a large patient cohort","volume":"51","author":"Haslak","year":"2024","journal-title":"J Rheumatol"},{"key":"ref17","article-title":"Rare diseases","year":"2016"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40290-020-00332-1","article-title":"Establishing patient registries for rare diseases: rationale and challenges","volume":"34","author":"Boulanger","year":"2020","journal-title":"Pharmaceut Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"832063","DOI":"10.3389\/fendo.2022.832063","article-title":"Rare disease registries are key to evidence-based personalized medicine: highlighting the European experience","volume":"13","author":"K\u00f6lker","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.2169\/internalmedicine.4793-24","article-title":"Idiopathic multicentric Castleman's disease as a mimicker of IgG4-related disease","volume":"64","author":"Yoshimi","year":"2024","journal-title":"Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"105731","DOI":"10.1016\/j.jbspin.2024.105731","article-title":"VEXAS syndrome: a new mimicker of idiopathic multicentric Castleman disease","volume":"91","author":"Philip","year":"2024","journal-title":"Joint Bone Spine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"ref24","article-title":"EUR-Lex-32016R0679-EN-EUR-Lex","year":""},{"key":"ref25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy","volume":"6","author":"Mukherjee","year":"2022","journal-title":"Blood Adv"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman\u2019s disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1634\/theoncologist.2011-0075","article-title":"Castleman\u2019s disease: systematic analysis of 416 patients from the literature","volume":"16","author":"Talat","year":"2011","journal-title":"Oncologist"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/rheumatology\/keac481","article-title":"Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis","volume":"62","author":"Gonz\u00e1lez Garc\u00eda","year":"2023","journal-title":"Rheumatology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/rheumatology\/kead644","article-title":"Lymphadenopathy in the rheumatology practice: a pragmatic approach","volume":"63","author":"Rodolfi","year":"2024","journal-title":"Rheumatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00296-020-04684-4","article-title":"Systemic lupus erythematosus complicated with Castleman disease: a case-based review","volume":"41","author":"Demirkan","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3109\/14397595.2014.985356","article-title":"Multicentric Castleman disease mimicking IgG4-related disease: a case report","volume":"27","author":"Izumi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ajh.26783","article-title":"Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy","volume":"98","author":"Bayram","year":"2023","journal-title":"Am J Hematol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1172\/JCI131332","article-title":"Targeting the mTOR pathway in idiopathic multicentric Castleman disease","volume":"129","author":"Stern","year":"2019","journal-title":"J Clin Invest"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","article-title":"IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report","volume":"30","author":"Galeotti","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1158\/1535-7163.MCT-10-0156","article-title":"Successful treatment of Castleman\u2019s disease with interleukin-1 receptor antagonist (Anakinra)","volume":"9","author":"El-Osta","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4274\/tjh.galenos.2024.2023.0477","article-title":"Ruxolitinib for the treatment of refractory idiopathic multicentric Castleman disease: a case report","volume":"41","author":"Gao","year":"2024","journal-title":"Turk J Haematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e29261","DOI":"10.1002\/pbc.29261","article-title":"Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series","volume":"68","author":"Lust","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ajh.10310","article-title":"Alleviation of systemic manifestations of multicentric Castleman\u2019s disease by thalidomide","volume":"73","author":"Lee","year":"2003","journal-title":"Am J Hematol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11684-017-0510-2","article-title":"Salvage therapy with lenalidomide containing regimen for relapsed\/refractory Castleman disease: a report of three cases","volume":"11","author":"Zhou","year":"2017","journal-title":"Front Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1038\/bcj.2015.12","article-title":"Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman\u2019s disease","volume":"5","author":"Lin","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjh.19000","article-title":"Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice","volume":"203","author":"Yin","year":"2023","journal-title":"Br J Haematol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/10428194.2021.1999437","article-title":"A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed\/refractory iMCD","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/14397595.2016.1206243","article-title":"A case of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, successfully treated with corticosteroid and cyclosporine a","volume":"29","author":"Takasawa","year":"2019","journal-title":"Mod Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2169\/internalmedicine.55.4710","article-title":"Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome","volume":"55","author":"Yamaga","year":"2016","journal-title":"Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1620\/tjem.236.289","article-title":"Successful treatment of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, with cyclosporine a: possible pathogenetic contribution of interleukin-2","volume":"236","author":"Konishi","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1579182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:38:51Z","timestamp":1756877931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1579182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":49,"alternative-id":["10.3389\/fmed.2025.1579182"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1579182","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"1579182"}}